The second webinar in the Precision Oncology Showcase series, sponsored by SOPHiA GENETICS, will highlight the successful decentralization of MSK-ACCESS® on the SOPHiA DDM™ Platform. We will explore findings from our internal verification study, insights from early adopter sites, and real-world data that demonstrate how our collaboration with Memorial Sloan Kettering Cancer Center (MSK) has overcome decentralization challenges—delivering high analytical concordance with single-site testing.

We are also excited to welcome Leah Thompson, MB (ASCP)CM, Lab Technician at Tennessee Oncology, who will share her experience verifying and implementing MSK-ACCESS® powered by SOPHiA DDM™. She will discuss analytical performance, workflow simplicity, and the ease of integrating the solution into a laboratory setting.

Key Discussion Points:

• Decentralizing MSK-ACCESS® – Challenges and solutions for ensuring analytical accuracy, managing site variability, and optimizing workflows.
• Performance & Validation – How the SOPHiA DDM™ Platform maintains high concordance through advanced analytics, noise reduction, and standardized wet-lab processes.
• Real-World Adoption – Leah Thompson, MB (ASCP)CM shares insights on assay verification, workflow efficiency, and the ease of use in routine lab operations.

Learning Objectives:

• Understand the Challenges of Decentralization – Learn about the complexities involved in decentralizing MSK-ACCESS® and how the SOPHiA DDM™ Platform addresses key hurdles such as analytical accuracy, wet-lab standardization, and noise reduction.
• Evaluate Performance and Real-World Verification – Gain insights into the internal verification study results and real-world data from seven early adopter sites, demonstrating high analytical concordance between the decentralized and single-site versions of MSK-ACCESS®
• Explore Ease of Adoption and Workflow Efficiency – Understand how MSK-ACCESS® powered with SOPHiA DDM™ offers a streamlined workflow, reliable data quality, and a straightforward implementation process for laboratories.

June 3, 2026 | 1:00PM SGT

Traditional genomic analysis often requires sequential testing or a “one-size-fits-all” comprehensive genomic profiling (CGP) panel, leading to time-consuming workflows and increased costs. MSK-IMPACT® Flex powered with SOPHiA DDM™ is a modular, end-to-end CGP solution built on the expertly designed content of MSK-IMPACT®. The flexible design enables agile analysis and high-resolution profiling of complex biomarkers (including TMB, MSI, HRD, and gene- and exon-level CNVs) from DNA capture, RNA capture, and low-pass whole genome sequencing. 

In this session, you will:  

• Learn how a modular approach simplifies workflows by allowing you to tailor biomarker coverage to each case 
• Explore compelling cases where combined data inputs enhanced the analysis of complex biomarkers 
• Hear real-world insights from OncoHelix on integrating SOPHiA DDM™ into the CGP ecosystem, including the benefits of complementing tissue analysis with tumor-normal liquid biopsy  

Speakers:

Dr. Rehan Mujeeb Faridi, PhD, HCLD/CC (ABB), Director of Molecular Diagnostics, OncoHelix
Lina Li, Director, Product Management, Application, SOPHiA GENETICS
Izabela Matyszczak, Technical Product Management Expert, SOPHiA GENETICS

June 17, 2026 | 1:00 PM SGT

Liquid biopsy has emerged as a revolutionary technology in the precision medicine field, by offering a non-invasive alternative to traditional tumor biopsies. While its potential for tumor detection and monitoring continues to grow, global adoption remains limited due to technical, workflow, and access-related barriers.​ In a leading partnership with AstraZeneca, SOPHiA GENETICS is expanding access to liquid biopsy testing through the deployment of MSK-ACCESS® powered with SOPHiA DDM™, a best-in-class and decentralized NGS-based assay. ​

Join this insightful workshop to explore how a decentralized approach enables broader patient access to testing and accelerates pharmaceutical development, setting new standards in precision oncology.

In this session you will:​

• Discover how the SOPHiA GENETICS decentralised approach and advanced analytics enables scalable, robust, and reproducible liquid biopsy testing, through its decentralized approach, supported by large-scale evidence generation studies across local deployments.​
• Gain insights into the clinical impact and utility of adopting MSK-ACCESS® powered with SOPHiA DDM™, and how it improves access and outcomes for cancer patients.​
• Explore how decentralized testing strategies support late-stage pharmaceutical development and drive commercial success in precision medicine.​

SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.

 More information is coming soon!

Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. We are excited to engage with the pathology community and share how our technology helps transform complex data into practical insights.

Visit our page again shortly for more information!

SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. Find us at Booth #13 where our team of experts will be ready to discuss how SOPHiA DDM™ platform is helping laboratories and healthcare institutions advance data-driven oncology insights. 

Come explore our partnership with the Memorial Sloan Kettering Cancer Center and our latest updates across the MSK solutions portfolio, including enhanced CNV detection with tumor purity and ploidy analysis in MSK-IMPACT® Flex, and new capabilities in MSK-ACCESS® including MSI and ctDNA fraction, now available on GEN2. 

Also learn more about OncoKB™ which is now fully embedded in SOPHiA DDM™ oncology workflows, and what that means for somatic variant interpretation in practice. 

Industry Symposium

Join our Industry Symposium to explore how combining MSK-IMPACT® Flex and MSK-ACCESS® on the SOPHiA DDM™ Platform unlocks deeper, more complete oncology insights. From real-world use cases to the latest liquid biopsy enhancements, this is a must-attend session for those looking to take their genomic profiling further. 

Monday, 15 June  | 2:30pm – 3:30pm | Ballroom 

Integrating tissue and liquid biopsy for in-depth precision oncology insights 

Dr. Maria De Bonis, Biologist and Health Manager, Fondazione Policlinico A. Gemelli IRCCS, Italy 
Lina Li, Product Director of Solid Tumors, SOPHiA GENETICS 

ASCO 2026 Edition

The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29^th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.

Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.

Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.

Across different sessions, the forum will explore:

• From One Lab to the World: Liquid Biopsy as a Leapfrog Technology
• The Power of the Network in Expanding Access to Advanced NGS Liquid Biopsy
• Strategic Partnerships: The Engine Drivers
• Leading Advances in Precision Oncology with Open Innovation

Don't miss this unique opportunity and reserve your spot now!

Le invitamos a participar en este exclusivo encuentro que reunirá a expertos y líderes clínicos para explorar los avances más recientes en medicina de precisión y genómica aplicada.

El evento contará con la participación del Presidente de SOPHiA GENETICS, quien compartirá la visión global de la compañía, así como con especialistas que abordarán el impacto de NGS en hemato-oncología y las tendencias futuras del área.

Asimismo, el evento destacará experiencias reales de clientes que compartirán su práctica clínica utilizando la plataforma SOPHiA DDM™, ofreciendo una perspectiva concreta sobre su impacto en el diagnóstico y la toma de decisiones.

A continuación, encontrará la agenda preliminar del evento.

What: SOPHiA GENETICS Exclusive Networking event

Where: Savoy Hotel

Date: 21 de abril

Time: 19:00 - 22:00

Agenda

Why Attend?

Discover SOPHiA DDM™ – One platform, universally compatible, endless possibilities

Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders

Tackle practical challenges

Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.

Network with thought leaders

Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform

El GENOMiCS INSIGHTS Day Bogotá se llevará a cabo el próximo 23 de abril, en el Hotel W Bogotá.

Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.

Durante la jornada abordaremos temas clave como la visión global de innovación de SOPHiA GENETICS, las nuevas posibilidades clínicas de la biopsia líquida, experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™, y nuevas oportunidades para ampliar el análisis genómico mediante exomas optimizados.

Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.

A continuación, encontrará la agenda preliminar del evento.

What: SOPHiA GENETICS Exclusive Networking event

Where: Hotel W Bogotá

Date: 23 de abril

Time: 16:00 - 19:00

Agenda

Why Attend?

Discover SOPHiA DDM™ – One platform, universally compatible, endless possibilities

Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders

Tackle practical challenges

Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.

Network with thought leaders

Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform

Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK

In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.

The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.

Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.